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Abstract
Glucose-induced reactive oxygen species (ROS) production initiates podocyte apoptosis, which represents a novel early
mechanism leading to diabetic nephropathy (DN). Here, we tested the hypothesis that Astragaloside IV(AS-IV) exerts
antioxidant and antiapoptotic effects on podocytes under diabetic conditions. Apoptosis, albuminuria, ROS generation,
caspase-3 activity and cleavage, as well as Bax and Bcl-2 mRNA and protein expression were measured in vitro and in vivo.
Cultured podocytes were exposed to high glucose (HG) with 50, 100 and 200 mg/ml of AS-IV for 24 h. AS-IV significantly
attenuated HG-induced podocyte apoptosis and ROS production. This antiapoptotic effect was associated with restoration
of Bax and Bcl-2 expression, as well as inhibition of caspase-3 activation and overexpression. In streptozotocin (STZ)-induced
diabetic rats, severe hyperglycemia and albuminuria were developed. Increased apoptosis, Bax expression, caspase-3
activity and cleavage while decreased Bcl-2 expression were detected in diabetic rats. However, pretreatment with AS-IV
(2.5, 5, 10 mg?kg
21?d
21) for 14 weeks ameliorated podocyte apoptosis, caspase-3 activation, renal histopathology,
podocyte foot process effacement, albuminuria and oxidative stress. Expression of Bax and Bcl-2 mRNA and protein in
kidney cortex was partially restored by AS-IV pretreatment. These findings suggested AS-IV, a novel antioxidant, to prevent
Glucose-Induced podocyte apoptosis partly through restoring the balance of Bax and Bcl-2 expression and inhibiting
caspase-3 activation.
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Introduction
Diabetic nephropathy (DN) is an important and common
complication of both type 1 and type 2 diabetes leading to end-
stage renal disease (ESRD). Podocytes are terminally differentiated
cells reside on the outer surface of the glomerular basement
membrane (GBM) and play a key role in maintaining the structure
and function of the glomerular filtration barrier. There is common
agreement that podocytes have a central role in the development
of proteinuria, which is a hallmark of almost all glomerular
diseases [1]. In human type 1 and type 2 diabetes mellitus [2–4],
the podocyte number is reduced not only in individuals with DN,
but also in subjects with short duration of diabetes before the onset
of microalbuminuria [4,5]. Studies in type 1 and type 2 diabetes
also demonstrated that podocyte depletion and loss represented
one of the earliest mechanisms in the pathogenesis of DN [6,7].
High glucose (HG) induced podocyte apoptosis in vitro and in vivo
[7], and podocyte apoptosis contributed to podocyte loss and
reduced podocyte number [8]. The study demonstrated that
podocyte apoptosis coincided with the onset of urinary albumin
excretion and preceded apparent podocyte loss in experimental
diabetic models [7]. These studies indicate that DN may directly
stem from podocyte injury. Thus, podocytes become a promising
target for the development of new renal-protective drugs for DN.
The increased production of ROS played a critical role in the
pathogenesis of DN. HG induced ROS production and accumu-
lation of H2O2 in podocytes [9]. Furthermore, glucose-induced
ROS production initiated podocyte apoptosis, which represented a
novel early pathomechanism leading to DN in experimental type 1
and type 2 diabetic models [7]. Recent study futher confirmed that
production of ROS by CYP4A monooxygenases, 20-HETE, and
Nox oxidases was involved in apoptosis of podocytes in vitro and
in vivo [10]. These results strongly suggest that ROS-mediated
podocyte apoptosis is a novel early mechanism leading to DN.
Thus, the concept of ROS-mediated podocyte apoptosis, associ-
ated with hyperglycemia, puts forth new and important opportu-
nities to effectively prevent the development and progression of
DN. However, there are no current interventions for DN
specifically preventing podocyte apoptosis.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39824Astragaloside IV(AS-IV) was a saponin purified from Astragalus
membranaceus (Fisch) Bge, which has been widely used in
traditional Chinese medicine to treat renal diseases for a long
time [11,12]. It has been reported that AS-IV has an antioxidant
effect and can ameliorate ischemia reperfusion (IR)-induced injury
in brain [13] and heart [14]. However, the protective effects of AS-
IV on apoptosis and oxidative stress in diabetic podocytes have not
been investigated yet. We previously reported that AS-IV
attenuated HG-induced podocyte detachment [15]. The aim of
this study is to further examine the preventive effects of AS-IV on
glucose-induced oxidative stress and podocyte apoptosis in vitro
and in vivo, and then provide a novel drug therapy for the
prevention of DN.
Materials and Methods
Drug preparation
Astragaloside IV(AS-IV) was purchased from Xi’an Sobeo
Pharmaceutical Technology Company, Limited (purity above
98%, Xi’an, China). The chemical structure of Astragaloside IV
(C41H68O14, molecular weight=784) was described in our
previous study [15].
In vitro studies: Cell culture and AS-IV treatments
Conditionally immortalized mouse podocytes were kindly
provided by Dr. Peter Mundel (Division of Nephrology, Massa-
chusetts General Hospital, Harvard University) and were
conducted as previously described [16]. The cells have a
temperature-sensitive variant of the SV40 large T antigen
(tsA58) that is induced by interferon-c (IFN-c). The cells
proliferate at 33uC with IFN-c, whereas the temperature 37uC
without IFN-c shifts the cells to differentiation. In brief, podocytes
were maintained in RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum (FCS, Gibco, USA), 100 U/ml
penicillin and 100 mg/ml streptomycin. Cells were grown at
33uC with 10 U/ml mouse recombinant interferon-c (IFN-c,
Sigma Chemical Corporation, USA). At confluence podocytes
were incubated at 37uC on collagen-coated dishes for 14 days
deprived of IFN-c to allow differentiation. Differentiated podo-
cytes were cultured for 24 h in RPMI 1640 medium and 1% FCS
before being exposed to various experimental conditions. AS-IV
was dissolved in dimethylsulfoxide (DMSO) and the final DMSO
concentration did not exceed 0.1% (v/v). The cells were divided
into the following groups: (1) normal glucose group (NG) as
controls incubated in RPMI 1640 containing 5 mM glucose, (2)
high glucose group (HG) incubated in RPMI 1640 containing
30 mM glucose, (3) mannitol group (MA) incubated in NG
medium supplemented with 25 mM D-mannitol (Sigma, USA) as
an osmotic control, (4) AS-IV group incubated in HG medium
treated with different concentrations of AS-IV(50, 100, 200 mg/
ml) for 24 h. All the glucose used in the present study was D-
glucose. All experimental groups were cultured in quadruplicate.
In vivo studies: animal study and experimental design
All work with rat was approved by the Animal Ethics
Committee of Fudan University, Shanghai, China and was
performed in accordance with the ‘‘Guide for the Care and Use
of Laboratory Animals’’ published by the National Institutes of
Health. Healthy male Sprague-Dawley rats weighing 180 to 200 g,
purchased from Experimental Animal Center, Fudan University,
Shanghai, China, were housed in an air-conditioned room at
2361uC with alternating 12 h cycles of light and dark. Animals
were fed a standard diet and given water ad libitum. Diabetes was
induced by a single intraperitoneal injection of streptozotocin
(STZ) at 65 mg/kg in rats. Age-matched control rats received an
equal volume of vehicle (0.1 M citrate buffer, pH 4.5). Forty-eight
hours after injection of STZ, the blood glucose level was measured
from the tail vein. Rats with a blood glucose level over 300 mg/dl
were considered as diabetic rats. To investigate the preventive
effects of AS-IV, AS-IV treatment (2.5, 5, 10 mg?kg
21?d
21) was
started 2 weeks before STZ injection and lasted 14 weeks. The
animals were divided into five groups (n=8/each group): (1)
Normal Sprague-Dawley rats as control (NC), (2) STZ-induced
diabetic rats (DN), (3) STZ-induced diabetic rats treated with low
dose of AS-IV at 2.5 mg?kg
21?d
21 (AL), (4) STZ-induced diabetic
rats treated with moderate dose of AS-IV at 5 mg?kg
21?d
21 (AM)
and (5) STZ-induced diabetic rats treated with high dose of AS-IV
at 10 mg?kg
21?d
21 (AH). AS-IV was suspended in 1% carbox-
ymethyl cellulose (CMC) solution at different concentrations and
was given to the DN rats by oral gavage once daily. Normal rats
(NC) received the same volume of CMC as control. Rats were kept
in individual metabolic cages for 24 h urine collection at the end of
4, 8 and 12 weeks after STZ injection. Urine was centrifuged at
800 g for 10 min at 25uC. Whole urine was stored at 270uC and
thawed just before use. Urinary albumin excretion (UAE) was
measured using an ELISA Kit (Nanjing Jiancheng Bioengineering
Institute, Nanjing, China) according to the manufacturer’s
method. At the end of 12 week after STZ, blood samples obtained
from the tail vein were assayed for blood glucose and HbA1c
levels. At the end of the study, rats were anesthetized with
pentobarbital sodium and the blood samples were taken through
the abdominal aorta for measuring biochemical parameters,
including blood urea nitrogen (BUN), creatinine (Cr) and alanine
aminotransferase (ALT), by an automatic biochemistry analyzer
(Hitachi Model 7600, Japan). Animals were then killed and the
kidneys were harvested immediately. The cortex from transversely
bisected left kidneys was snap-frozen in liquid nitrogen and stored
at 270uC for protein and total RNA extraction. That of the right
kidneys was fixed with 10% buffered formalin and embedded in
paraffin for histological evaluation. The kidneys were cut into
4 mm sections and stained with hematoxylin and eosin. The
sections were then examined by light microscopy.
Electron microscopy studies
To determine the structural changes in podocyte morphology,
electron microscopic morphometric evaluation was carried out
performed by routine procedures. Renal cortex samples were cut
into 1 mm
3 pieces on ice, immediately fixed in 2.5% glutaralde-
hyde, and then embedded. Ultrathin sections were examined by
electron microscopy. All electron microscope photomicrographs
were evaluated in a blind fashion.
Apoptosis assay
Apoptotic nuclei were detected using Hoechst 33258 staining.
Podocytes were exposed to the different experimental conditions as
indicated above. Cells were fixed with 4% paraformaldehyde for
10 min at room temperature and stained by Hoechst 33258
(Sigma, USA) for 30 min at room temperature. After that, cells
were washed twice using PBS for 3 min. Apoptosis was identified
by nuclear condensation and/or fragmentation. The percentage of
apoptotic cells was counted on using fluorescent microscopy.
The apoptotic podocytes were also quantified by fluorescence-
activated cell sorting (FACS) scan after Annexin V-fluorescein
isothiocyanate (FITC) and propidium iodide (PI) labeling as
described in the manufacturer’s protocol (Roche). After 24 h
incubation with the indicated stimuli, cultured podocytes were
washed twice using cold phosphate-buffered saline (PBS) on ice,
trypsinized, and pelleted by centrifugation at 200 g for 5 min. The
Astragaloside IV Prevents Podocyte Apoptosis
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buffer. After that, cells were stained with Annexin V-FITC and PI.
The stained cells were then analyzed for apoptosis using FACS
scan. Cells positive for Annexin V–FITC and negative for PI were
considered apoptotic.
A transferase-mediated dUTP nick-end labeling (TUNEL) assay
was performed to detect apoptotic nuclei in kidney sections [8,17].
TUNEL assay was conducted using a TUNEL detection kit
(Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s instruction. Apoptosis was measured by the
pathologist who was blinded to the treatment animals had
received. A minimum of five fields per slide and six slides per
group were counted by this method. Positive cells were counted as
podocytes when residing on the outer surface of GBM. Cells
residing in areas circumscribed by GBM were counted as
endocapillary or mesangial cells. Apoptotic cells with nuclei
staining dark brown were counted by light microscopy. For
quantitative analysis, TUNEL-positive cells were quantified by
counting five different fields at 4006 magnification with two
independent investigators who was blinded to the treatment that
the animals had received.
Caspase-3 Activity Assay
Caspase-3 activity in lysates from cultured podocytes and kidney
cortex was determined using the Caspase-3 Colorimetric Assay Kit
(Nanjing KeyGEN Biotech. Co., Ltd. Nanjing, China), according
to the manufacturer’s protocol. The protein concentration was
measured by the Bradford method. Caspase-3 activity was
expressed in terms of absorbance units (OD 405 nm) per
milligram of protein.
Determination of ROS production and levels of oxidative
stress markers
ROS generation in podocytes was measured with the fluores-
cent probe 29,79-dichlorodihydrofluorescin (DCF) diacetate as
previously described [18]. Briefly, podocytes were incubated for
45 min at 37uC with 50 mmol/l DCF diacetate. The DCF
fluorescence was determined in a multiwell fluorescence plate
reader.
The oxidative stress markers, including activities of catalase
(CAT) and superoxide dismutase (SOD), and content of mal-
ondialdehyde (MDA) in kidney cortex and cultured mouse
podocytes were determined using the assay kits (Nanjing Jiancheng
Bioengineering Institute, Nanjing, China), according to the
manufacturer’s instruction.
Western blotting
Kidney cortex or cultured podocytes under different experi-
mental conditions were lysed in lysis buffer with a sonicator. Crude
lysates were centrifuged at 10,000 rpm for 5 min at 4uC. Total
protein concentration from the resultant supernatant was deter-
mined by the bicinchoninic acid (BCA) protein assay (Pierce,
Rockford, IL, USA). Reduced protein samples were separated by
sodium dodecyl sulfate (SDS)/polyacrylamide gel electrophoresis,
transferred to a polyvinylidene difluoride membrane (Immobilon-
P, Millipore, Bedford, Mass, USA) by electroblotting. Membranes
were incubated overnight at 4uC with the following primary
antibodies: anti-Bax and anti-Bcl-2 antibodies (Santa Cruz
Biotechnology, CA, USA), anti-cleaved caspase-3 antibody (Cell
Signaling Technology, MA CA, USA). Negative controls were
performed without primary antibody. After washing, the second-
ary antibody was added and incubated 1 h at room temperature
Figure 1. AS-IV dose-dependently inhibited HG-induced podocyte apoptosis, ROS production and caspase-3 activation. Effects of
AS-IV on apoptosis assessed by Hoechst staining (A) and FACS (B), ROS production (C) and caspase-3 activity (D). Podocytes were exposed to NG, MA,
HG, HG with 50, 100, 200 mg/ml of AS-IV for 24 h, respectively. NG, normal glucose (5 mM glucose); MA, mannitol (25 mM D-mannitol); HG, high
glucose (30 mM glucose). Results are expressed as the means 6 SD. *P,0.05 vs NG.
#P,0.05 vs HG.
doi:10.1371/journal.pone.0039824.g001
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Arlington Heights, IL, USA). The membranes were then stripped
and re-probed with anti-b-actin antibody (Sigma, USA). Densito-
metric quantitation was performed using a Bio-Rad VersaDoc
imaging system model 5000 with Bio-Rad Quantity One software.
Protein expression was quantified as the ratio of specific band to b-
actin.
Real-time quantitative RT-PCR
Total RNA from kidney cortex or cultured podocytes was
isolated by the Trizol procedure (Invitrogen, Carlsbad, CA, USA).
Then, 1 mg of total RNA was reverse transcribed using the
SuperScript RT kit from Invitrogen (Carlsbad, USA). Quantitative
RT-PCR was performed using the ABI PRISM7900 Sequence
Detection System (Applied Biosystems) with SYBR Green Master
Mix and three-step standard cycling conditions and sequence-
specific primers. Primer concentrations were determined by
preliminary experiments that analyzed the optimal concentrations
of each primer. The following sequence-specific oligonucleotide
primers for mouse podocytes were used for PCRs: Bax sense
GTTTCATCCAGGATCGAGCAG and anti-sense AGCT-
GAGCGAGTGTCTCCGGCG; Bcl-2 sense CTGAGTACCT-
GAACCGGCATC and anti-sense GAGCAGCGTCTTCAGA-
GACAG. The following sequence-specific oligonucleotide primers
for rat kidney tissue were used for PCRs: Bax sense AGA-
CACCTGAGCTGACCTTGGA and anti-sense CGCTCAGC-
TTCTTGGTGGAT; Bcl-2 sense GGGATGCCTTTGTG-
GAACTATATG and anti-sense CAGCCAGGAGAAATC-
AAACAGA. In order to confirm amplification specificity, the
PCR products from each primer pair were subjected to a melting
curve analysis and subsequent agarose gel electrophoresis. A
control without cDNA was run in parallel with each assay. Each
reaction was amplified in triplicate and ratio results were
calculated based on the 2
2DDCT method as described previously
[19]. Relative mRNA levels were normalized to those of GAPDH.
Statistical analysis
Statistics were conducted by SPSS 13.0 software. All data were
expressed as means 6 standard deviation (SD). The significance of
differences among experimental groups was determined by
ANOVA analysis. When a significant difference was detected,
the data were further analyzed by Dunnett’s multiple range test. A
value of P,0.05 was considered statistically significant.
Results
AS-IV protected mouse podocytes from apoptosis
induced by high glucose (HG)
The apoptosis of podocytes was examined by two different
methods in vitro. As shown in Hoechst staining, exposure to HG
for 24 h resulted in a significant podocyte apoptosis compared
with NG control (Fig. 1A). MA had no effect on cell apoptosis.
Figure 2. AS-IV dose-dependently lowered MDA content while elevated activities of CAT and SOD in HG-stimulated podocytes.
Effects of AS-IV on content of MDA (A) and activities of CAT (B) and SOD (C) in podocytes. MDA, malondialdehyde; CAT, catalase; SOD, superoxide
dismutase. Results are expressed as the means 6 SD. *P,0.05 vs NG.
#P,0.05 vs HG.
doi:10.1371/journal.pone.0039824.g002
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tosis in a concentration-dependent manner, with the maximal
effect achieved at a dose of 200 mg/ml (Fig. 1A). The effect of AS-
IV on podocyte apoptosis was also determined by FACS after
Annexin V-FITC and PI labeling. Likewise, AS-IV reduced the
podocyte apoptosis at concentration of 50, 100 and 200 mg/ml,
respectively, when compared with HG control (Fig. 1B). Taken
Figure 3. AS-IV decreased Bax mRNA and caspase-3 protein expression while increased Bcl-2 mRNA expression in podoctyes. Effects
of AS-IV on cleaved caspase-3 protein expression (A), and mRNA expression of Bax (B) and Bcl-2 (C) in HG-stimulated podocytes. The Bax and Bcl-2
mRNA expression was examined by Real-time RT-PCR. Results are expressed as the means 6 SD. *P,0.05 vs NG.
#P,0.05 vs HG.
doi:10.1371/journal.pone.0039824.g003
Figure 4. AS-IV downregulated Bax protein expression and upregulated Bcl-2 protein expression in podoctyes. Effects of AS-IV on
protein expression of Bax and Bcl-2 in HG-stimulated podocytes. The protein expression of Bax and Bcl-2 was examined by Western blotting. Results
are expressed as the means 6 SD. *P,0.05 vs NG.
#P,0.05 vs HG.
doi:10.1371/journal.pone.0039824.g004
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apoptosis.
AS-IV reduced the HG-induced ROS production and
oxidative stress in podocytes
ROS played an important role in the pathogenesis of podocyte
apoptosis in DN, we investigated the effects of AS- IV on ROS
generation in podocytes. Compared with incubation in NG,
exposure to HG for 24 h significantly induced ROS production
(P,0.05). Exposure to MA for 24 h did not change the ROS level
in podocytes. However, HG-induced ROS production was
partially reduced by AS-IV in a dose-dependent manner
(Fig. 1C). Moreover, the concentration of MDA and the activities
of superoxide anion radical-scavenging enzymes, SOD and CAT
in cultured podocytes were presented in Figure 2. Exposure to HG
for 24 h resulted in a remarkable increase in levels of MDA
(Fig. 2A) and a dramatical reduction in activities of CAT (Fig. 2B)
and SOD (Fig. 2C), which were prevented by AS-IV treatment in
a concentration-dependent manner (Fig. 2 A–C). These results
demonstrated that AS-IV treatment significantly decreased the
amount of a product of lipid peroxidation while increased the
activities of antioxidant enzymes in cultured podocytes. Therefore,
AS- IV effectively inhibited HG-induced ROS generation and
oxidative stress in HG-stimulated podocytes.
AS-IV suppressed the caspase 3 activation and
overexpression in HG-stimulated podocytes
Apoptosis was further verified by detection of caspase-3 activity
and Western blot analysis of caspase-3 cleavage. Exposure of
podocytes to AS-IV resulted in a substantial decrease in the
caspase 3 activity and caspase cleavage. HG-induced caspase 3
activation was restored by AS- IV in a concentration-dependent
manner (Fig. 1D). AS- IV also dose-dependently downregulated
the protein expression of cleaved caspase-3 (Fig. 3A). These results
indicated that the antiapoptotic effect of AS-IV on podocytes was
caspase-3 dependent.
AS-IV regulated the mRNA and protein expression of Bax
and Bcl-2 in HG-stimulated podocytes
HG elevated Bax mRNA expression and decreased Bcl-2
mRNA expression, which was abrogated by AS-IV treatment in a
dose-dependent manner evident at a dose as low as 50 mg/ml
(Fig. 3, B and C). In contrast, MA had no effect on mRNA
expression of Bax (Fig. 3B) and Bcl-2 (Fig. 3C). Consistent with
these effects on mRNA expression, HG for 24 h increased the
amount of Bax protein and decreased the amount of Bcl-2 protein
compared with NG. MA did not affect protein production of Bax
and Bcl-2 while AS-IV treatment partially restored the balance of
Bax and Bcl-2 protein expression in podocytes under HG
condition (P,0.05) (Fig. 4). These findings indicated that the
antiapoptotic effect of AS-IV was associated with regulation of the
balance of Bax and Bcl-2 mRNA and protein expression.
In vivo studies: Effects of AS-IV on body weight and
metabolic parameters in blood
To validate these findings in cultured immortalized mouse
podocytes, we established rat model of DN induced by intraper-
itoneal injection of STZ to test the hypothesis that AS-IV prevents
podocytes apoptosis in vivo. Blood glucose (BG) and glycated
hemoglobin (HbA1c) levels were significantly increased in STZ-
induced diabetic rats (P,0.05 vs. normal conrol rats). However,
no differences in BG and HbA1c levels were observed between
AS-IV treated and untreated STZ-induced diabetic rats (Table 1).
In diabetic rats at the end of 12 weeks after STZ injection, body
weight was decreased compared with normal rats and did not
change compared with rats that pretreated with AS-IV(Table 2).
Additionally, AS-IV did not change the levels of blood urea
nitrogen (BUN), serum creatinine (SCr) and alanine aminotrans-
ferase (ALT) in rats (Table 1), indicating that AS-IV had no toxic
side effects to the liver and renal function.
AS-IV significantly ameliorated the renal histopathology,
podocyte foot process effacement, albuminuria and
oxidative stress in STZ-induced diabetic rats
Mesangial matrix expansion is considered a hallmark of diabetic
nephropathy. At 12 weeks after STZ injection, the diabetic rats
showed focal mesangial matrix expansion compared to normal
control rats and pretreatment with AS-IV ameliorated mesangial
expansion compared with the untreated STZ-induced diabetic rats
(Fig. 5). At 12 weeks after STZ injection, observation of podocyte
ultrastructure by electron microscopy revealed marked podocyte
foot process effacement in diabetic rats, whereas the rats
pretreated with AS-IV showed a marked reduction in podocyte
foot process effacement. AS-IV dose-dependently ameliorated
podocyte foot process effacement in diabetic rats (Fig. 6A). The
STZ-induced diabetic rats developed severe albuminuria when
compared with the nornmal control rats (P,0.05). Pretreatment
with AS-IV significantly alleviated proteinuria in diabetic rats.
Table 1. Metabolic and plasma biochemical parameters.
Group
BG
(mg/dl)
HbA1c
(%)
ALT
(U/L)
BUN
(mmol/L)
SCr
(mmol/L)
NC 175.1624.1 4.2960.13 60.665.6 5.4860.50 29.265.8
DN 624.4675.1* 9.7960.56* 62.667.1 6.1460.47 33.865.2
AL 605.0650.7* 9.5060.64* 64.565.5 5.7660.80 32.064.7
AM 586.6664.7* 9.3760.70* 63.963.4 5.9860.41 31.266.1
AH 573.1645.7* 9.2760.45* 66.167.1 5.6660.39 28.466.8
BG, blood glucose; HbA1c, hemoglobin A1c; BUN, blood urea nitrogen; SCr,
serum creatinine; ALT, alanine aminotransferase. AS-IV treatment was started 2
weeks before STZ injection and lasted 14 weeks. NC, normal control rats; DN,
STZ-induced diabetic rats; AL, DN rats treated with AS-IV (2.5 mg?kg
21?d
21);
AM, DN rats treated with AS-IV (5 mg?kg
21?d
21); AH, DN rats treated with AS-IV
(10 mg?kg
21?d
21).
*P,0.05 vs NC group.
doi:10.1371/journal.pone.0039824.t001
Table 2. Physical parameter and renal oxidative stress
markers.
Group BW (g)
MDA (nmol/mg
pro)
CAT (U/mg
pro)
SOD(U/mg
pro)
NC 523.1637.9 16.961.8 25.263.2 68.567.0
DN 231.3623.0* 37.064.3* 12.261.9* 38.863.1*
AL 249.0635.8* 28.063.2
# 16.262.2
# 51.162.8
#
AM 240.0628.3* 23.862.4
# 18.662.5
# 55.363.5
#
AH 243.8633.6* 20.163.1
# 22.662.8
# 68.367.7
#
BW, body weight; MDA, malondialdehyde; CAT, catalase; SOD, superoxide
dismutase.
*P,0.05 vs NC group.
#P,0.05 vs DN group.
doi:10.1371/journal.pone.0039824.t002
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as low as as 2.5 mg?kg
21?d
21 (Fig. 6 B–D). AS-IV also decreased
albuminuria in diabetic rats in a time-dependent manner, which
was evident in as little as 4 weeks after STZ injection (Fig. 6B). AS-
IV at dose of 10 mg?kg
21?d
21 reduced the albuminuria by 48% at
12 weeks after STZ injection, which reached the peak effect
(Fig. 6D). Moreover, AS-IV dose-dependently inhibited the
oxidative stress in diabetic rats through decreasing the MDA
content and increasing the activities of antioxidant enzymes (CAT
and SOD) (Table 2).
AS-IV prevented podocyte apoptosis in vivo
To determine if AS-IV has a similar anti-apoptotic effect in vivo
that we have demonstrated in vitro, we assessed podocyte
apoptosis in diabetic rats by TUNEL staining. There was a
significant decrease in apoptotic podocytes in kidney sections from
STZ-induced diabetic rats pretreated with AS-IV. This antiapop-
totic effect was dose-dependent, which was as little as
2.5 mg?kg
21?d
21 of AS-IV (AL group), and the maximal
inhibition was achieved by 10 mg?kg
21?d
21 of AS-IV (AH group)
(Fig. 7A).
AS-IV inhibited the caspase-3 activation and
overexpression in STZ-induced diabetic rats
The caspase-3 activity and cleavage in kidney cortex from STZ-
induced diabetic rats were measured. Similar to the results from in
vitro study, AS-IV dose-dependently reduced caspase-3 activation
(Fig. 7B) and caspase-3 overexpression (Fig. 7C) in STZ-induced
diabetic rats.
AS-IV restored the balance of Bax and Bcl-2 mRNA and
protein expression in STZ-induced diabetic rats
Hyperglycemia-induced apoptosis was associated with increased
Bax expression and decreased Bcl-2 expression at protein (Fig. 8A)
and mRNA (Fig. 8, B and C) levels, which were partially restored
by AS-IV in a dose-dependent manner. These effects were dose-
dependent, which were evident at a dose as low as
2.5 mg?kg
21?d
21 and reached the maximal effect at
10 mg?kg
21?d
21 of AS-IV(Fig. 8 A–C).
Discussion
Our study is the first to demonstrate the preventive effect of AS-
IV, a novel antioxidant, on glucose-induced podocyte apoptosis,
which has potentially important clinical consequences. This anti-
apoptotic effect was shown by three different types of apoptosis
assays. AS-IV dose-dependently inhibited high glucose (HG)-
induced podocyte apoptosis in vitro. The studies in STZ-induced
diabetic rats further demonstrated that pretreatment with AS-IV
significantly ameliorated the renal histopathology, podocyte foot
process effacement, albuminuria and oxidative stress. Moreover,
glucose-induced podocyte apoptosis was associated with upregula-
tion of Bax expression and downregulation of Bcl-2 expression, as
well as caspase-3 activation and overexpression, which were
partially restored by AS-IV in a dose-dependent manner. Taken
together, AS-IV prevented glucose-induced podocyte apoptosis in
vitro and in vivo, and these novel findings provided new insights
into the development of kidney-protective drug through directly
targeting podocytes.
There is mounting evidence demonstrating that podocytes have
a central role in the progression of glomerular diseases and these
glomerulopathies therefore are considered as podocytopathies [1].
However, most of the available therapies for renal diseases are
unspecific and offer partial cures at best because these treatment
options do not primarily focus on podocytes but rather act
systemically and thus cause side effects. Thus, there is urgent need
to develop potential drug therapy for proteinuria and kidney
disease through direct podocyte targeting [20]. Recently, much
work has demonstrated that podocyte apoptosis plays an
important role in the pathogenesis of proteinuria and glomerulo-
sclerosis in DN [21–24]. Experimental and clinical studies have
shown that a decrease in podocyte number due to apoptosis or
detachment leads to proteinuria in DN [3,4,25]. Therefore,
preventing or inhibiting podocyte apoptosis should become an
obvious and promising therapeutic target for treatment of DN.
Figure 5. AS-IV ameliorated the renal histopathology in diabetic rats at 12 weeks after STZ injection. AS-IV treatment (2.5, 5,
10 mg?kg
21?d
21) was started 2 weeks before STZ injection and lasted 14 weeks. NC, normal control rats; DN, STZ-induced diabetic rats; AL, DN rats
treated with AS-IV (2.5 mg?kg
21?d
21); AM, DN rats treated with AS-IV (5 mg?kg
21?d
21); AH, DN rats treated with AS-IV (10 mg?kg
21?d
21).
doi:10.1371/journal.pone.0039824.g005
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ing podocyte apoptosis in DN.
Interestingly, the first major finding in this study was that AS-
IV, one of the major and active components of the Astragalus
membranaceus (Fisch) Bge, significantly prevented podocytes from
apoptosis both in vitro and in vivo. We performed Hoechst
staining, FACS after Annexin V-FITC and PI labeling, as well as
TUNEL assay to exactly detect the podocyte apoptosis. Our
previous study has verified that these methods are very accurate
and reliable [26]. In the present study, HG induced ROS
generation and podocyte apoptosis, which consisted with previous
studies [7,10]. This apoptotic effect was not due to an osmotic
effect of HG because an equivalent concentration of D-mannitol
did not cause the above result. However, AS-IV effectively
inhibited the HG-induced podocyte apoptosis in a dose-dependent
manner and this effect was evident at a dose as low as 50 mg/ml.
The maximal inhibition of podocytes apoptosis by AS-IV was
obtained at a dose of 200 mg/ml. Moreover, AS-IV reduced HG-
induced ROS production in a dose-dependent manner. We also
examined the effects of AS-IV on the content of MDA and the
activities of antioxidant enzymes, CAT and SOD, in mouse
podocytes cultured in HG. There was an increase in MDA level,
as well as a decrease in CAT and SOD activities in podocytes
exposed to HG, which was ameliorated by AS-IV treatment in a
dose-dependent manner. Thus, AS-IV affected the oxidant-
antioxidant balance in mouse podocytes. In vivo study further
confirmed that pretreatment with AS-IV also dose-dependently
reduced podocyte apoptosis. Podocyte apoptosis is an early
glomerular phenotype that leads to progressive podocyte depletion
and albuminuria, and oxidative stress played a critical role in the
pathogenesis of podocyte apoptosis in DN [7,10]. AS-IV has been
found to have antioxidant effects both in vivo and in vitro [14]. In
the present study, we also demonstrated that AS-IV reduced
oxidative stress both in cultured podocytes and in kidney cortex
from STZ-induced diabetic rats. The activities of antioxidant
enzymes (CAT, SOD) were significantly increased and the MDA
content decreased in AS-IV treated rats when compared with
those in the untreated STZ-induced diabetic rats, suggesting a
significant antioxidant effect of AS-IV. Furthermore, AS-IV
ameliorated the albuminuria, renal histopathology and podocyte
Figure 6. AS-IV dose-dependently ameliorated podocyte foot process effacement and reduced the albuminuria in diabetic rats.
Effects of AS-IV on glomerular ultrastructure (A) and albuminuria in diabetic rats at 4 weeks (B), 8 weeks (C) and 12 weeks (D) after STZ injection. UAE,
urinary albumin excretion. Results are expressed are the means 6 SD (n=8/each group). *P,0.05 vs NC.
#P,0.05 vs DN.
doi:10.1371/journal.pone.0039824.g006
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findings, we reasoned that AS-IV might improve podocyte
survival, preserve podocyte number and reduce the albuminuria,
therefore ultimately delay the progression of DN. This protective
effect was partly attributed to its anti-oxidant action.
To explore the mechanisms underlying the antiapoptotic action
of AS-IV, we examined the levels of Bax (proapoptotic) and Bcl-2
(antiapoptotic) proteins. It has been shown that Bax mediates
podocyte apoptosis induced by TGF-b [8]. Decreased expression
of Bcl-2 in podocytes is associated with progressive glomerular
Figure 7. AS-IV dose-dependently prevented podocyte apoptosis, caspase-3 activation and overexpression in diabetic rats. Effects
of AS-IV on podocyte apoptosis detected by TUNEL assay (A), caspase-3 activity (B) and cleaved caspase-3 protein expression (C) in diabetic rats at 12
weeks after STZ injection. Results are expressed are the means 6 SD. *P,0.05 vs NC.
#P,0.05 vs DN.
doi:10.1371/journal.pone.0039824.g007
Figure 8. AS-IV restored the balance of Bax and Bcl-2 mRNA and protein expression in diabetic rats. Effects of AS-IV on protein
expression of Bax and Bcl-2 (A), as well as mRNA expression of Bax (B) and Bcl-2 (C) in diabetic rats at 12 weeks after STZ injection. The protein
expression of Bax and Bcl-2 was examined by Western blotting. The mRNA expression of Bax and Bcl-2 was examined by Real-time RT-PCR. Results are
expressed are the means 6 SD. *P,0.05 vs NC.
#P,0.05 vs DN.
doi:10.1371/journal.pone.0039824.g008
Astragaloside IV Prevents Podocyte Apoptosis
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39824injury and clinical indices of poor renal prognosis in human IgA
nephropathy [27]. The study in STZ-induced diabetic rats has
demonstrated the increased expression of Bax and decreased Bcl-2
expression in renal glomeruli detected by immunohistochemical
staining [23,28]. In the present study, we further determined the
mRNA and protein expression of Bax and Bcl-2 by real-time
quantitative RT-PCR and Western blotting. We observed similar
alterations in Bax and Bcl-2 expression in response to hypergly-
cemia. Our study showed that glucose induced apoptosis in vitro
and in vivo, accompanied by an increase in Bax expression and a
decrease in Bcl-2 expression, which were prevented by AS-IV
treatment in a dose-dependent manner. Thus, AS-IV protects
against podocyte apoptosis partly by restoring the balance of Bax
and Bcl-2 proteins.
We further investigated the effects of AS-IV on the key
downstream effector of apoptosis, caspase-3 activity and cleavage.
Caspase-3 is an effector caspase and involved in many forms of
apoptosis [29]. Activation of caspase-3 is the important determi-
nant of apoptosis. Caspase-3 operates as the key effector enzyme in
cell death through receptor-mediated (Fas/FasL) or mitochondria-
dependent (Bax/Bcl-2)-induced apoptosis. In this study, caspase-3
acitivity and expression was increased both in HG-stimulated
podocytes and in kidney cortex from diabetic rats, which consisted
with the previous studies [7,28]. AS-IV dose-dependently reduced
caspase-3 activation and overexpression in vitro and in vivo. More
importantly, the inhibitory effect of AS-IV on podocyte apoptosis
paralleled the reduction in caspase-3 activation and overexpres-
sion. Therefore, the antiapoptotic effect of AS-IV on podocytes is
caspase-3 dependent.
The above results indicate that AS-IV, a novel antioxidant,
prevents glucose- induced podocyte apoptosis in vitro and in vivo,
which is associated with decreasing Bax expression and inhibiting
caspase-3 activation while increasing Bcl-2 expression.
Finally, we examined the blood glucose and HbA1c levels in
rats. AS-IV exhibited no effects on the levels of blood glucose and
HbA1c, thus the preventive effects of AS-IV on podocyte apoptosis
and albuminuria were independent of the blood glucose levels.
Moreover, we measured the levels of blood urea nitrogen,
creatinine and alanine aminotransferase and tested the safety of
AS-IV in rats. AS-IV had no toxic side effects to the liver and renal
function in these rats, indicating that AS-IV may become a safe
and effective drug for treatment of DN. In our preliminary study
in rats, we chose the doses of AS-IV at 2.5, 5, 10 mg?kg
21?d
21,
and we found that these doses could effectively reduce proteinuria
and did not cause any toxicity. So these doses were chosen in our
study.
In addition, a recent study has shown that AS-IV can reduce
blood pressure in fructose-fed rats [30]. Therefore, We cannot
exclude the possibility that some effects of AS-IV on podocyte’s
function may at least in part be induced by AS-IV mediated
decrease of the blood pressure. These effects need further
investigation.
There is growing evidence of gender-specific aspects in
podocyte biology and renal diseases. Sex hormones may mediate
the effects of gender on chronic renal disease. Several studies have
demonstrated that aging male rats develop proteinuria and
glomerulosclerosis, whereas female and estrogen-treated male rats
are resistant to disease progression [31–33]. Data from meta-
analysis studies indicate that men exhibit a more rapid age-related
decline in renal function than women and several renal diseases
appear to be gender-dependent [34]. Furthermore, recent report
demonstrates that estrogen receptor alpha expression in podocytes
protects against apoptosis in vitro and in vivo [35]. In this study,
severe hyperglycemia and albuminuria, as well as increased
apoptosis were developed in male rats with DN. However,
whether gender plays a role in promoting podocyte apoptosis
and progression of diabetic kidney diseases needs further study.
In summary, our results demonstrate for the first time that AS-
IV acts directly on podocytes. AS-IV, a novel antioxidant,
prevents podocyte apoptosis and reduces albuminuria in DN
partly through decreasing Bax expression and inhibiting caspase-3
activation while increasing Bcl-2 expression. These findings
strengthen the therapeutic rationale for AS-IV in the treatment
of DN and also provide new insights into the development of
kidney-protective drug through directly targeting podocytes.
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